Cargando…

A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment

ABSTRACTS: BACKGROUND: Clomiphene citrate (CC) is most commonly used as a first-line treatment of infertility. However, a disturbance of endometrial growth by the adverse effects of the CC has been recognized. Since a thin endometrium is recognized as a critical factor of implantation failure, preve...

Descripción completa

Detalles Bibliográficos
Autores principales: Takasaki, Akihisa, Tamura, Hiroshi, Taketani, Toshiaki, Shimamura, Katsunori, Morioka, Hitoshi, Sugino, Norihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880974/
https://www.ncbi.nlm.nih.gov/pubmed/24369731
http://dx.doi.org/10.1186/1757-2215-6-94
_version_ 1782298135684448256
author Takasaki, Akihisa
Tamura, Hiroshi
Taketani, Toshiaki
Shimamura, Katsunori
Morioka, Hitoshi
Sugino, Norihiro
author_facet Takasaki, Akihisa
Tamura, Hiroshi
Taketani, Toshiaki
Shimamura, Katsunori
Morioka, Hitoshi
Sugino, Norihiro
author_sort Takasaki, Akihisa
collection PubMed
description ABSTRACTS: BACKGROUND: Clomiphene citrate (CC) is most commonly used as a first-line treatment of infertility. However, a disturbance of endometrial growth by the adverse effects of the CC has been recognized. Since a thin endometrium is recognized as a critical factor of implantation failure, preventing CC-induced thinning of the endometrium is important. This study was undertaken to investigate whether the modified CC treatments are useful to prevent a thin endometrium in patients undergoing CC treatments. METHODS: This study is a prospective, randomized controlled study. The study was performed at the Saiseikai Shimonoseki General Hospital during a 4-month period (May 2012 to September 2012). Sixty-six infertile women who had a thin endometrium (< 8 mm) during the standard CC treatment (50 mg/day on days 5–9 of the menstrual cycle) were enrolled. The patients were randomly divided into three groups: 22 patients were given 25 mg/day CC on days 5–9 (half-dose group), 22 patients were given 50 mg/day CC on days 1–5 (early administration group) and 22 patients received a standard CC treatment again (control group). Endometrial thickness at the induction of ovulation was assessed by ultrasonography. The primary endpoint of this study was an endometrial thickness. RESULTS: Half dose administration and early administration improved the endometrial thickness (≥ 8 mm) in 14 patients (70%) and in 19 patients (90%) respectively, while only 3 patients (15%) improved in endometrial thickness in the control group. The mean endometrial thickness was also significantly higher in the half dose group (8.6 ± 1.5 mm) and early administration group (9.4 ± 1.5 mm) compared to the control group (6.7 ± 1.8 mm). No side effect was observed in this study. CONCLUSIONS: The modified treatment with a half-dose or early administration of CC significantly increased endometrial thickness in patients with a history of thin endometrium caused by the standard CC regimen. The modified CC treatments in this study can be beneficial for patients with a thin endometrium as a result of standard CC treatment. TRIAL REGISTRATION: Clinical Trial Registration Number: UMIN000007959.
format Online
Article
Text
id pubmed-3880974
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38809742014-01-07 A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment Takasaki, Akihisa Tamura, Hiroshi Taketani, Toshiaki Shimamura, Katsunori Morioka, Hitoshi Sugino, Norihiro J Ovarian Res Research ABSTRACTS: BACKGROUND: Clomiphene citrate (CC) is most commonly used as a first-line treatment of infertility. However, a disturbance of endometrial growth by the adverse effects of the CC has been recognized. Since a thin endometrium is recognized as a critical factor of implantation failure, preventing CC-induced thinning of the endometrium is important. This study was undertaken to investigate whether the modified CC treatments are useful to prevent a thin endometrium in patients undergoing CC treatments. METHODS: This study is a prospective, randomized controlled study. The study was performed at the Saiseikai Shimonoseki General Hospital during a 4-month period (May 2012 to September 2012). Sixty-six infertile women who had a thin endometrium (< 8 mm) during the standard CC treatment (50 mg/day on days 5–9 of the menstrual cycle) were enrolled. The patients were randomly divided into three groups: 22 patients were given 25 mg/day CC on days 5–9 (half-dose group), 22 patients were given 50 mg/day CC on days 1–5 (early administration group) and 22 patients received a standard CC treatment again (control group). Endometrial thickness at the induction of ovulation was assessed by ultrasonography. The primary endpoint of this study was an endometrial thickness. RESULTS: Half dose administration and early administration improved the endometrial thickness (≥ 8 mm) in 14 patients (70%) and in 19 patients (90%) respectively, while only 3 patients (15%) improved in endometrial thickness in the control group. The mean endometrial thickness was also significantly higher in the half dose group (8.6 ± 1.5 mm) and early administration group (9.4 ± 1.5 mm) compared to the control group (6.7 ± 1.8 mm). No side effect was observed in this study. CONCLUSIONS: The modified treatment with a half-dose or early administration of CC significantly increased endometrial thickness in patients with a history of thin endometrium caused by the standard CC regimen. The modified CC treatments in this study can be beneficial for patients with a thin endometrium as a result of standard CC treatment. TRIAL REGISTRATION: Clinical Trial Registration Number: UMIN000007959. BioMed Central 2013-12-27 /pmc/articles/PMC3880974/ /pubmed/24369731 http://dx.doi.org/10.1186/1757-2215-6-94 Text en Copyright © 2013 Takasaki et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Takasaki, Akihisa
Tamura, Hiroshi
Taketani, Toshiaki
Shimamura, Katsunori
Morioka, Hitoshi
Sugino, Norihiro
A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment
title A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment
title_full A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment
title_fullStr A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment
title_full_unstemmed A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment
title_short A pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment
title_sort pilot study to prevent a thin endometrium in patients undergoing clomiphene citrate treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880974/
https://www.ncbi.nlm.nih.gov/pubmed/24369731
http://dx.doi.org/10.1186/1757-2215-6-94
work_keys_str_mv AT takasakiakihisa apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT tamurahiroshi apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT taketanitoshiaki apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT shimamurakatsunori apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT moriokahitoshi apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT suginonorihiro apilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT takasakiakihisa pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT tamurahiroshi pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT taketanitoshiaki pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT shimamurakatsunori pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT moriokahitoshi pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment
AT suginonorihiro pilotstudytopreventathinendometriuminpatientsundergoingclomiphenecitratetreatment